Prophylactic fluconazole in liver transplant recipients - A randomized, double-blind, placebo-controlled trial

被引:174
作者
Winston, DJ
Pakrasi, A
Busuttil, RW
机构
[1] Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Med Ctr, Dumont UCLA Transplant Ctr, Los Angeles, CA 90095 USA
关键词
liver transplantation; fluconazole; mycoses; cyclosporine; Candida;
D O I
10.7326/0003-4819-131-10-199911160-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Among persons who receive solid organ transplants, liver transplant recipients have the highest incidence of invasive fungal infection; however, no antifungal prophylaxis has been proven to be effective. Objective: To evaluate the efficacy and safety of prophylactic fluconazole in liver transplant recipients. Design: Randomized, double-blind, placebo-controlled trial. Setting: University-affiliated transplantation center. Patients: 212 liver transplant recipients who received fluconazole (400 mg/d) or placebo until 10 weeks after transplantation. Measurements: Fungal colonization, proven superficial or invasive fungal infection, drug-related side effects, and death. Results: Fungal colonization increased in patients who received placebo (from 60% to 90%) but decreased in patients who received fluconazole (from 70% to 28%). Proven fungal infection occurred in 45 of 104 placebo recipients (43%) but in only 10 of 108 fluconazole recipients (9%) (P < 0.001). Fluconazole prevented both superficial infection (29 of 104 placebo recipients became infected [28%] compared with 4 of 108 fluconazole recipients [4%]; P < 0.001) and invasive infection (24 of 104 placebo recipients became infected [23%] compared with 6 of 108 fluconazole recipients [6%]; P < 0.001). Fluconazole prevented infection by most Candida species, except C. glabrata. However, infection and colonization by organisms intrinsically resistant to fluconazole did not seem to increase. Fluconazole was not associated with any hepatotoxicity. Patients receiving fluconazole had higher serum cyclosporine levels and more adverse neurologic events (headaches, tremors, or seizures in 13 fluconazole recipients compared with 3 placebo recipients; P < 0.01). Although the overall mortality rate was similar in both groups (12 of 108 [11%] in the fluconazole group compared with 15 of 104 [14%] in the placebo group; P > 0.2), fewer deaths related to invasive fungal infection were seen in the fluconazole group (2 of 108 patients [2%]) than in the placebo group (13 of 104 patients [13%]) (P = 0.003). Conclusions: Prophylactic fluconazole after liver transplantation decreases fungal colonization, prevents superficial and invasive fungal infections, and has no appreciable hepatotoxicity. Although fluconazole prophylaxis is associated with fewer deaths from fungal infection,it does not improve overall survival. Patients receiving prophylactic fluconazole require close monitoring of serum cyclosporine levels to avoid neurologic toxicity.
引用
收藏
页码:729 / +
页数:10
相关论文
共 30 条
[1]   The epidemiology of hematogenous candidiasis caused by different Candida species [J].
AbiSaid, D ;
Anaissie, E ;
Uzun, O ;
Raad, I ;
Pinzcowski, H ;
Vartivarian, S .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) :1122-1128
[2]   COMPARATIVE EFFECTS OF THE ANTIMYCOTIC DRUGS KETOCONAZOLE, FLUCONAZOLE, ITRACONAZOLE AND TERBINAFINE ON THE METABOLISM OF CYCLOSPORINE BY HUMAN LIVER-MICROSOMES [J].
BACK, DJ ;
TJIA, JF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (05) :624-626
[3]   1,000 LIVER-TRANSPLANTS - THE LESSONS LEARNED [J].
BUSUTTIL, RW ;
SHAKED, A ;
MILLIS, JM ;
JURIM, O ;
COLQUHOUN, SD ;
SHACKLETON, CR ;
NUESSE, BJ ;
CSETE, M ;
GOLDSTEIN, LI ;
MCDIARMID, SV .
ANNALS OF SURGERY, 1994, 219 (05) :490-499
[4]  
CASTALDO P, 1991, ARCH SURG-CHICAGO, V126, P149, DOI 10.1001/archsurg.1991.01410260033005
[5]   RISK-FACTORS FOR INVASIVE FUNGAL-INFECTIONS COMPLICATING ORTHOTOPIC LIVER-TRANSPLANTATION [J].
COLLINS, LA ;
SAMORE, MH ;
ROBERTS, MS ;
LUZZATI, R ;
JENKINS, RL ;
LEWIS, WD ;
KARCHMER, AW .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) :644-652
[6]  
COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
EMMANOUILIDES C, 1996, TRANSPLANTATION LIVE, P633
[9]   A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
GOODMAN, JL ;
WINSTON, DJ ;
GREENFIELD, RA ;
CHANDRASEKAR, PH ;
FOX, B ;
KAIZER, H ;
SHADDUCK, RK ;
SHEA, TC ;
STIFF, P ;
FRIEDMAN, DJ ;
POWDERLY, WG ;
SILBER, JL ;
HOROWITZ, H ;
LICHTIN, A ;
WOLFF, SN ;
MANGAN, KF ;
SILVER, SM ;
WEISDORF, D ;
HO, WG ;
GILBERT, G ;
BUELL, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851
[10]   COMPARISON OF CYCLOSPORINE DETERMINATIONS IN WHOLE-BLOOD BY 3 DIFFERENT METHODS - HPLC, I-125 RIA AND H-3 RIA [J].
HUANG, WY ;
LIPSEY, AI ;
CHENG, MH .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (04) :528-532